HFM Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$162K Buy
2,813
+76
+3% +$4.36K 0.06% 30
2026
Q1
$166K Buy
2,737
+34
+1% +$1.98K 0.06% 25
2025
Q4
$146K Buy
2,703
+43
+2% +$2.07K 0.06% 31
2025
Q3
$120K Buy
2,660
+27
+1% +$1.26K 0.05% 30
2025
Q2
$122K Buy
2,633
+55
+2% +$2.7K 0.05% 28
2025
Q1
$157K Buy
+2,578
New +$150K 0.08% 24

Other funds holding BMY

HFM Investment Advisors's BMY Position: Q2 2026 in Review

HFM Investment Advisors increased its Bristol-Myers Squibb (BMY) stake by 2.8% in Q2 2026, buying an estimated $4.36K and bringing the position to 2,813 shares worth $162K. The position accounts for 0.06% of the portfolio, ranked #30.

HFM Investment Advisors first reported a position in BMY in Q1 2025 and has held it in 6 quarters since. The position peaked at $166K in Q1 2026. 2,526 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • HFM Investment Advisors held 2,813 shares of Bristol-Myers Squibb worth $162K as of Q2 2026.
  • HFM Investment Advisors bought 76 Bristol-Myers Squibb shares in Q2 2026, an estimated $4.36K.
  • Bristol-Myers Squibb made up 0.06% of HFM Investment Advisors's portfolio in Q2 2026, its #30 holding.
  • HFM Investment Advisors first reported a position in Bristol-Myers Squibb in Q1 2025 and has held it in 6 quarters since.
  • HFM Investment Advisors's Bristol-Myers Squibb position peaked at $166K in Q1 2026.
  • 2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.